Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Shift4 Payments Q1 2026 Earnings Call - International Expansion and AI-Driven Efficiency Drive Growth Amid Geopolitical Headwinds
Shift4 Payments delivered solid Q1 2026 results, with gross revenue less network fees (GRLNF) up 49% year-over-year to $549 million and adjusted EBITDA up 39% to $234 million. The company navigated a ...
- Gross revenue less network fees (GRLNF) grew 49% year-over-year to $549 million, in line with guidance.
- Adjusted EBITDA increased 39% year-over-year to $234 million, maintaining a 43% margin.
- Payments-based revenue less network fees surged 25% year-over-year, with worldwide growth reaching 51% and Americas growth at 15%.
- +7 more takeaways
Host Hotels & Resorts Q1 2026 Earnings Call - Raising 2026 Guidance on Resort Strength and Capital Discipline
Host Hotels & Resorts reported a strong first quarter, delivering adjusted EBITDAre of $543 million and raising its full-year comparable hotel RevPAR guidance to 3%-4.5%. The outperformance was driven...
- Host Hotels raised its 2026 comparable hotel RevPAR guidance to 3%-4.5% and total RevPAR to 3.5%-5%, citing resilient demand and strong out-of-room spending trends.
- First quarter adjusted EBITDAre reached $543 million, a 5.6% increase year-over-year, driven by rate growth and a 70 basis point expansion in comparable hotel EBITDA margins.
- Resort properties in Florida and Phoenix led transient revenue growth, which jumped 5.5% year-over-year, as affluent consumers shifted travel to U.S. destinations amid geopolitical uncertainty.
- +7 more takeaways
MKS Instruments Q1 2026 Earnings Call - AI-Driven Complexity Fuels Record Revenue and Aggressive Q2 Guidance
MKS Instruments delivered a blistering Q1 2026, crushing guidance with $1.08 billion in revenue and $2.30 in EPS. The semiconductor and electronics segments are riding a dual wave of AI infrastructure...
- Q1 2026 revenue hit $1.08 billion, up 15% year-over-year and 4% sequentially, surpassing the high end of guidance.
- Semiconductor revenue grew 13% year-over-year to $466 million, driven by broad-based strength in DRAM, NAND, and logic applications.
- Electronics and packaging revenue surged 27% year-over-year to $321 million, fueled by flexible PCB drilling and AI-related chemistry demand.
- +11 more takeaways
"Lantheus" Q1 2026 Earnings Call - PSMA Franchise Transition and Regulatory Milestones Drive 2027 Growth
Lantheus delivered a solid Q1 2026 start, with revenue of $377.3 million driven by PYLARIFY, Neuraceq, and DEFINITY. The company secured FDA approval for PYLARIFY TruVu and received tentative approval...
- Q1 2026 revenue reached $377.3 million, a 1.2% year-over-year increase, or 8.6% adjusted for divested SPECT revenues.
- PYLARIFY U.S. volume grew 5.8% year-over-year, with stable net ASP and sequential performance despite competitive pressures.
- Neuraceq revenue jumped 14.3% sequentially to $35.4 million, driven by Alzheimer’s DMT adoption and expanded PMF footprint.
- +7 more takeaways
Stevanato Group Q1 2026 Earnings Call - GLP-1 Demand Drives 10% Revenue Growth as Engineering Segment Faces Slow Order Intake
Stevanato Group kicked off fiscal 2026 with 10% constant-currency revenue growth, fueled by a 13% jump in its drug containment and delivery solutions (BDS) segment. High-value solutions, including pre...
- Revenue grew 10% on a constant currency basis to EUR 273.6 million, with the BDS segment up 13% and the engineering segment down 31%.
- GLP-1 therapies represented 21%-22% of total Q1 revenue, driving a 15% increase in biologics demand and reinforcing a long-term secular tailwind.
- High-value solutions accounted for 47% of total revenue, up 17% year-over-year, with prefillable syringes and EZ-fill vials leading the growth.
- +7 more takeaways
Amylyx Pharmaceuticals Q1 2026 Earnings Call - Avexitide LUCIDITY Trial Nearing Top-Line Readout with NDA Drafting Underway
Amylyx Pharmaceuticals advanced its pipeline in Q1 2026, with the phase III LUCIDITY trial for avexitide fully enrolled and poised for top-line data in Q3 2026. The company is simultaneously drafting ...
- Phase III LUCIDITY trial for avexitide fully enrolled, with top-line data expected in Q3 2026
- NDA drafting underway to accelerate regulatory submission timeline if trial results are positive
- Expanded access program launched for up to 250 U.S. patients with post-bariatric hypoglycemia (PBH)
- +7 more takeaways
Albemarle Q1 2026 Earnings Call - Specialties Guidance Raised Amid Strong Lithium Pricing
Albemarle delivered a powerful first quarter, with net sales jumping 33% year-over-year to $1.4 billion and adjusted EBITDA more than doubling to $664 million. The surge was driven by a 51% increase i...
- Net sales surged 33% year-over-year to $1.4 billion, driven by higher volumes and pricing across both energy storage and specialties segments.
- Adjusted EBITDA more than doubled year-over-year to $664 million, reflecting a 20 percentage point increase in margin due to pricing and cost discipline.
- Energy storage lithium pricing jumped 51% year-over-year, with volumes up 14%, while energy storage EBITDA skyrocketed 196%.
- +7 more takeaways
Peloton Q3 FY2026 Earnings Call - Revenue Rebounds as Capital Returns Loom
Peloton delivered its first year-over-year revenue growth in fiscal 2026, hitting $631 million in Q3 and beating guidance by $6 million. The win came from a disciplined pivot from pure connected fitne...
- Q3 total revenue reached $631 million, beating guidance by $6 million and marking the first year-over-year revenue growth in fiscal 2026.
- Free cash flow surged 59% year-over-year to $151 million, while adjusted EBITDA rose 41% to $126 million.
- Net debt plummeted 70% year-over-year to $173 million, leaving the company with $1.13 billion in cash and a net leverage ratio of 0.4.
- +7 more takeaways
Xometry Q1 2026 Earnings Call - Record Growth and Strategic Siemens Partnership Drive Market Share Gains
Xometry delivered a record Q1 2026 with revenue growing 36% year-over-year to $205 million, driven by a 40% surge in marketplace revenue and expanding margins. Adjusted EBITDA jumped to $10.5 million,...
- Q1 2026 revenue grew 36% year-over-year to $205 million, with marketplace revenue surging 40% and accelerating 600 basis points sequentially from Q4.
- Adjusted EBITDA reached $10.5 million, a $10.4 million improvement year-over-year, marking the fourth consecutive quarter of margin expansion.
- Active buyer count grew 20% year-over-year to 85,581, with net adds of 3,760, the highest in nine quarters, driven by product-led growth and efficient marketing.
- +9 more takeaways
Viatris Q1 2026 Earnings Call - China Growth Accelerates to 18% as Pipeline Catalysts Mount
Viatris delivered a clean Q1 2026 beat with total revenues of $3.5 billion, up 3% year over year, and adjusted EBITDA of $1 billion. The standout story is Greater China, where sales surged 18% as e-co...
- Total revenues reached $3.5 billion, up 3% year over year on an operational basis, with adjusted EBITDA of $1 billion.
- Greater China was the clear growth driver, with sales surging 18% year over year as e-commerce channels doubled and commercial investments took hold.
- Management raised full year China growth expectations from low single digits to mid to high single digits, though policy risk remains a monitoring item.
- +10 more takeaways